222 related articles for article (PubMed ID: 19109557)
1. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Karp JE; Flatten K; Feldman EJ; Greer JM; Loegering DA; Ricklis RM; Morris LE; Ritchie E; Smith BD; Ironside V; Talbott T; Roboz G; Le SB; Meng XW; Schneider PA; Dai NT; Adjei AA; Gore SD; Levis MJ; Wright JJ; Garrett-Mayer E; Kaufmann SH
Blood; 2009 May; 113(20):4841-52. PubMed ID: 19109557
[TBL] [Abstract][Full Text] [Related]
2. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Jabbour E; Kantarjian H; Ravandi F; Garcia-Manero G; Estrov Z; Verstovsek S; O'Brien S; Faderl S; Thomas DA; Wright JJ; Cortes J
Cancer; 2011 Mar; 117(6):1236-44. PubMed ID: 20960519
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.
Ding H; McDonald JS; Yun S; Schneider PA; Peterson KL; Flatten KS; Loegering DA; Oberg AL; Riska SM; Huang S; Sinicrope FA; Adjei AA; Karp JE; Meng XW; Kaufmann SH
Haematologica; 2014 Jan; 99(1):60-9. PubMed ID: 23996484
[TBL] [Abstract][Full Text] [Related]
4. Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Karp JE; Vener TI; Raponi M; Ritchie EK; Smith BD; Gore SD; Morris LE; Feldman EJ; Greer JM; Malek S; Carraway HE; Ironside V; Galkin S; Levis MJ; McDevitt MA; Roboz GR; Gocke CD; Derecho C; Palma J; Wang Y; Kaufmann SH; Wright JJ; Garret-Mayer E
Blood; 2012 Jan; 119(1):55-63. PubMed ID: 22001391
[TBL] [Abstract][Full Text] [Related]
5. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
Erba HP; Othus M; Walter RB; Kirschbaum MH; Tallman MS; Larson RA; Slovak ML; Kopecky KJ; Gundacker HM; Appelbaum FR
Leuk Res; 2014 Mar; 38(3):329-33. PubMed ID: 24411921
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
Sparano JA; Moulder S; Kazi A; Vahdat L; Li T; Pellegrino C; Munster P; Malafa M; Lee D; Hoschander S; Hopkins U; Hershman D; Wright JJ; Sebti SM
J Clin Oncol; 2006 Jul; 24(19):3013-8. PubMed ID: 16769985
[TBL] [Abstract][Full Text] [Related]
7. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.
Witzig TE; Tang H; Micallef IN; Ansell SM; Link BK; Inwards DJ; Porrata LF; Johnston PB; Colgan JP; Markovic SN; Nowakowski GS; Thompson CA; Allmer C; Maurer MJ; Gupta M; Weiner G; Hohl R; Kurtin PJ; Ding H; Loegering D; Schneider P; Peterson K; Habermann TM; Kaufmann SH
Blood; 2011 Nov; 118(18):4882-9. PubMed ID: 21725056
[TBL] [Abstract][Full Text] [Related]
8. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Lancet JE; Duong VH; Winton EF; Stuart RK; Burton M; Zhang S; Cubitt C; Blaskovich MA; Wright JJ; Sebti S; Sullivan DM
Clin Cancer Res; 2011 Mar; 17(5):1140-6. PubMed ID: 21233404
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Harousseau JL; Martinelli G; Jedrzejczak WW; Brandwein JM; Bordessoule D; Masszi T; Ossenkoppele GJ; Alexeeva JA; Beutel G; Maertens J; Vidriales MB; Dombret H; Thomas X; Burnett AK; Robak T; Khuageva NK; Golenkov AK; Tothova E; Mollgard L; Park YC; Bessems A; De Porre P; Howes AJ;
Blood; 2009 Aug; 114(6):1166-73. PubMed ID: 19470696
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J
Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
Karp JE; Smith BD; Gojo I; Lancet JE; Greer J; Klein M; Morris L; Levis MJ; Gore SD; Wright JJ; Garrett-Mayer E
Clin Cancer Res; 2008 May; 14(10):3077-82. PubMed ID: 18483374
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Lancet JE; Gojo I; Gotlib J; Feldman EJ; Greer J; Liesveld JL; Bruzek LM; Morris L; Park Y; Adjei AA; Kaufmann SH; Garrett-Mayer E; Greenberg PL; Wright JJ; Karp JE
Blood; 2007 Feb; 109(4):1387-94. PubMed ID: 17082323
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
Widemann BC; Salzer WL; Arceci RJ; Blaney SM; Fox E; End D; Gillespie A; Whitcomb P; Palumbo JS; Pitney A; Jayaprakash N; Zannikos P; Balis FM
J Clin Oncol; 2006 Jan; 24(3):507-16. PubMed ID: 16421428
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
Harousseau JL; Lancet JE; Reiffers J; Lowenberg B; Thomas X; Huguet F; Fenaux P; Zhang S; Rackoff W; De Porre P; Stone R;
Blood; 2007 Jun; 109(12):5151-6. PubMed ID: 17351110
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.
Brandwein JM; Leber BF; Howson-Jan K; Schimmer AD; Schuh AC; Gupta V; Yee KW; Wright J; Moore M; MacAlpine K; Minden MD;
Leukemia; 2009 Apr; 23(4):631-4. PubMed ID: 19092853
[TBL] [Abstract][Full Text] [Related]
16. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.
Yanamandra N; Buzzeo RW; Gabriel M; Hazlehurst LA; Mari Y; Beaupre DM; Cuevas J
J Pharmacol Exp Ther; 2011 Jun; 337(3):636-43. PubMed ID: 21378206
[TBL] [Abstract][Full Text] [Related]
17. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.
Burnett AK; Russell NH; Culligan D; Cavanagh J; Kell J; Wheatley K; Virchis A; Hills RK; Milligan D;
Br J Haematol; 2012 Aug; 158(4):519-22. PubMed ID: 22639959
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
Li T; Christos PJ; Sparano JA; Hershman DL; Hoschander S; O'Brien K; Wright JJ; Vahdat LT
Ann Oncol; 2009 Apr; 20(4):642-7. PubMed ID: 19153124
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
Jazieh K; Molina J; Allred J; Yin J; Reid J; Goetz M; Lim VS; Kaufmann SH; Adjei A
Invest New Drugs; 2019 Apr; 37(2):307-314. PubMed ID: 30171497
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli G; Iacobucci I; Paolini S; Ottaviani E
Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
